Ligand Pharmaceuticals Stock Sees Insider Sales Amid Analyst Upgrade
What happened
Royal Bank of Canada lifted its target price for Ligand Pharmaceuticals. Separately, a director of Ligand Pharmaceuticals sold 700 shares on November 2nd at an average price of $320.43, totaling $224,301.00. The director had also sold 1,411 shares on October 30th, valued at $451,858.64. These transactions were disclosed in filings with the SEC.
From themarketsdaily.com
Why it matters
The combination of an analyst upgrade from Royal Bank of Canada and the disclosure of insider selling by a director introduces mixed signals regarding Ligand Pharmaceuticals. The company recently reported $2.67 earnings per share in its quarterly results.
From themarketsdaily.com
Who's involved
- Ligand PharmaceuticalsBiopharmaceutical company whose stock was subject to the transaction and analyst review.
- Royal Bank of CanadaFinancial institution that provided financial analysis and lifted the target price for Ligand Pharmaceuticals.
- SECGovernment agency to which the stock transactions were formally disclosed.
- representativeDirector who sold shares of Ligand Pharmaceuticals stock.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Ligand PharmaceuticalsSpeculative
The mixed signals from the analyst upgrade and the director's selling could impact the market price of the company's stock.
Keep exploring
The entities involved
-
Ligand Pharmaceuticals
biopharmaceutical company based out of La Jolla, California
Nothing else this week.
-
Royal Bank of Canada
financial institution in Canada
-
SEC
Slovak company
Related events
- Monolithic Power Systems filed disclosures with the SEC, listed on Nasdaq, and saw Royal Bank of Canada increase its stock stake.
- Crescent Capital BDC, Inc. stock traded on the Nasdaq exchange and filings were made with the SEC on May 27, 2026.
- General Counsel of Arthur J. Gallagher & Co. sold company stock, while major banks issued rating and price target updates.
- Financial firms, including RBC, TD Cowen, Leerink Partners, and Morgan Stanley, raised price targets and provided coverage for Vertex Pharmaceuticals.
- Assembly Biosciences stock traded on Nasdaq, while UBS cut its price target but maintained a Buy rating, following an SEC disclosure.